https://www.patlynk.com/fr/trial/NCT00005044
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and...
OBJECTIVES: Compare the efficacy of moderate-duration (28 weeks) neoadjuvant total androgen suppression (TAS) and radiotherapy (RT) with short-duration (8 we
phase iii trialandrogen suppressionevaluatedurationneoadjuvant